Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Governance document

Draft funding and sponsorship policy

Consultation on the policy governing what funding the Institute accepts, from whom, and on what published terms. The draft prohibits any funding arrangement that confers rights of review over an assessment before publication, and requires that every funding…

Document identifier
CEI-CP-011
Series
Public comment period
Version
1.0
Published
24 Mar 2023
Last reviewed
24 Mar 2023
Next review
24 Mar 2024
Identifier
10.71829/cei.cp.11
Certainty
Not rated
Cycle
2023 Q1
Window
09 Jan 2023 – 10 Mar 2023
Status
Closed
Submissions
10

§1Consultation and window

§1.1Window

Opened
9 January 2023
Closed
10 March 2023
Duration
60 days
Status
Closed — the disposition is published
Document under consultation
Governance document
Submissions received
10

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the prohibition on pre-publication review drawn widely enough to capture arrangements that confer such rights indirectly?
  2. Should the Institute accept funding from a supplier it also assesses, subject to disclosure, or should such funding be refused outright?
  3. Is per-page disclosure proportionate, or does it dilute the signal by repeating it where it is not relevant?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The policy was ratified with amendments. The prohibition on pre-publication review was widened to cover indirect arrangements, and disclosure remains per-page after respondents divided on the question and the assessment committee preferred over-disclosure to a judgement call about relevance.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.